SCHEMBL203706

SCHEMBL203706

NC(=O)c1c(F)ccc(OCc2nc3cc(Cl)ccc3o2)c1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
ANO1 Q5XXA6 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
STAT3 P40763 1/20 0.39
LMNA P02545 4/20 0.39
CYP1A2 P05177 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
CETP P11597 4/20 0.38
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KCNH2 Q12809 1/20 0.37
AKR1B1 P15121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201188 0.88 ALOX5 (0.38) ANO1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL201516 0.86 ALOX5AP (0.34) MEN1KMT2AMAPTSMN1; SMN2STAT3
SCHEMBL203479 0.86 LOXL2 (0.43) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL204323 0.85 MEN1 (0.44) MEN1KMT2AMAPTSMN1; SMN2CETP
SCHEMBL202962 0.82 MAPT (0.45) MAPTSMN1; SMN2LMNACYP1A2CETP
SCHEMBL15278149 0.82 PARP3 (0.42) FFAR1PPARDPPARAANO1MEN1
SCHEMBL2704592 0.79 MRGPRX4 (0.41) CYP1A2
SCHEMBL202795 0.77 KDM4E (0.38) LMNAPOLB
SCHEMBL2707209 0.77 SGMS2 (0.39) MEN1KMT2AMAPTSMN1; SMN2LMNA
SCHEMBL17274987 0.77 PPARD (0.39) PPARDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
US-9475783-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-25 US disclosed
US-9475783-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-25 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150031694-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2015-01-29 US disclosed
US-20150031694-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2015-01-29 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
WO-2013142712-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-09-26 WO disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-20130072520-A2 ANTIBACTERIAL AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2013-03-21 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
US-8088791-B2 Antibacterial agents Biots Scientific Management Pty Ltd (AU) 2012-01-03 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072520-A2 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 FFAR1 754/4885PPARD 3689/4885PPARA 3049/4885
US-20150031694-A1 ANTIMICROBIAL AGENTS CFTR, MRPL21, ABCB11 FFAR1 2494/4885PPARD 3687/4885PPARA 3489/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 FFAR1 400/4885PPARD 3598/4885PPARA 2842/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 FFAR1 754/4885PPARD 3689/4885PPARA 3049/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 FFAR1 754/4885PPARD 3689/4885PPARA 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.